Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Unknown 1Active not recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Head & Neck 2Thoracic 1Sarcoma 1Other solid neoplasm 1Gynecologic 1Genitourinary 1Gastrointestinal 1Dermatologic 1Breast 1

Conditions

Carcinoma, Hepatocellular 35Carcinoma, Non-Small-Cell Lung 32Colorectal Neoplasms 19Esophageal Squamous Cell Carcinoma 18Stomach Neoplasms 17Squamous Cell Carcinoma of Head and Neck 16Rectal Neoplasms 11Cholangiocarcinoma 11Head and Neck Neoplasms 10Small Cell Lung Carcinoma 9Lung Neoplasms 9Esophageal Neoplasms 9Triple Negative Breast Neoplasms 8Uterine Cervical Neoplasms 7Nasopharyngeal Carcinoma 7Urinary Bladder Neoplasms 6Recurrence 6Pancreatic Neoplasms 6Neoplasms 6Colonic Neoplasms 6Melanoma 5Hodgkin Disease 5Biliary Tract Neoplasms 4Adenocarcinoma of Lung 4Sarcoma 3Non-Muscle Invasive Bladder Neoplasms 3Neoplasm Metastasis 3NSCLC 3Locally Advanced Rectal Cancer 3Liver Neoplasms 3

Interventions

Iodine-131 14trametinib 9dabrafenib 9Thyroidectomy 9Surgical Procedures, Operative 9lenvatinib 8Thyroxine 8Magnetic Resonance Spectroscopy 8pembrolizumab 7Paclitaxel 7anlotinib 6Thyrotropin Alfa 6selpercatinib 5Sorafenib 5Saline Solution 5Radiofrequency Ablation 5Everolimus 5pazopanib 4Vemurafenib 4Sunitinib 4Radiotherapy 4Nivolumab 4Fluorodeoxyglucose F18 4Dexmedetomidine 4Cyclophosphamide 4Biopsy, Fine-Needle 4Biopsy 4Bevacizumab 4apatinib 3Triiodothyronine 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
OTHER × Thyroid Neoplasms × tislelizumab × Clear all
NCT04802876 2025-03-21

ACROPOLI

SOLTI Breast Cancer Research Group

Phase 2 Active not recruiting
184 enrolled
BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckOther solid neoplasmSarcomaThoracic

Adenocarcinoma Of Esophagus, Adenocarcinoma of Lung, Squamous Cell Carcinoma of Head and Neck, Carcinoma, Ovarian Epithelial, Uveal Melanoma, Anus Neoplasms, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Carcinoma, Hepatocellular, Melanoma, Mesothelioma, Neoplasms, Unknown Primary, Sarcoma, Thyroid Neoplasms, Cholangiocarcinoma, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

NCT05659186 2022-12-21

PD-1 Inhibitor and Anlotinib Combined With Multimodal Radiotherapy in Recurrent or Metastatic Anaplastic Thyroid Cancer

West China Hospital

Phase 2 Unknown
20 enrolled
Head & Neck

Thyroid Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡